The Prostate
Papers 5332
1 page of 534 pages (5,332 results)
#1Oliver Sartor (Tulane University)H-Index: 64
#2Sreevalsa Appukkuttan (Bayer)H-Index: 2
Last. Che-Kai Tsao (Mount Sinai Hospital)
view all 4 authors...
BACKGROUND The most common site of disease in metastatic castration-resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium-223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases. However, administration requires a multidisciplinary approach and an infrastructure that supports coordination of care, which may differ by practice site. We aimed to evaluate practice patterns and treatment ...
#1Giuseppe Broggi (University of Catania)H-Index: 8
#2Arturo Lo Giudice (University of Catania)H-Index: 2
Last. Giorgio Ivan Russo (University of Catania)H-Index: 33
view all 0 authors...
OBJECTIVE To study the association between insulin receptors (isoforms α and β), insulin growth factor-1 (IGF1) and serine/arginine splicing factor 1 (SRSF-1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androg...
#1Amber E. de Groot (Johns Hopkins University)H-Index: 6
#2Kayla V. Myers (Johns Hopkins University)H-Index: 2
Last. Kenneth J. Pienta (Johns Hopkins University)H-Index: 138
view all 14 authors...
BACKGROUND Tumor-associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect the complete TME of a human patient or the natural initiation and progression of a tumor. Therefore, genetically engineered mouse models are essential for studying the TME as well as advancing TAM-targeted therapies. Two common transgenic (TG) models of prostate cancer are Hi-Myc and transgenic adenocarcinoma of t...
#1Dong-Yi Chen (CGU: Chang Gung University)H-Index: 12
#2Po-Jung Su (CGU: Chang Gung University)H-Index: 8
Last. Pao-Hsien Chu (CGU: Chang Gung University)H-Index: 20
view all 0 authors...
Background null We aimed to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive gonadotropin-releasing hormone (GnRH) agonist (GnRHa) therapy and those who receive GnRH antagonist therapy. null Methods null Using the Taiwan National Health Insurance Research Database, we analyzed data by comparing 666 participants receiving GnRH antagonists and 1332 propensity score-matched participants treated with GnRHa in a 1:2 fashion during the...
#1Shidong Lv (Southern Medical University)H-Index: 4
#2Xiaochun Pu (Southern Medical University)
Last. Qiang Dang (Southern Medical University)
view all 0 authors...
The androgen receptor (AR) plays an important role in the progression of prostate cancer and is the most important therapeutic target. However, androgen deprivation therapy will finally lead patients to progress to castration-resistant prostate cancer (CRPC). Here, we confirmed that GAS5, a long noncoding RNA, could interact and suppress AR transactivation in CRPC C4-2 cells. Knockdown GAS5 by short hairpin RNA would enhance the transcription of AR via promote AR recruitment to the promoter of i...
#1Mike Wenzel (Goethe University Frankfurt)H-Index: 6
#2Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
Last. Luis A. Kluth (Goethe University Frankfurt)H-Index: 20
view all 0 authors...
Background null Recently, an increase in the rates of high-risk prostate cancer (PCa) was reported. We tested whether the rates of and low, intermediate, high and very high-risk PCa changed over time. We also tested whether the number of prostate biopsy cores contributed to changes rates over time. null Methods null Within the Surveillance, Epidemiology and End Results (SEER) database (2010-2015), annual rates of low, intermediate, high-risk according to traditional National Comprehensive Cancer...
Objectives null This study aimed to externally validate the diagnostic accuracy of the Select MDx test for Significant prostate cancer (Sig PCa) (ISUP > 1), in a contemporaneous, prospective, multicenter cohort with a prostate-specific antigen (PSA) between 3 and 10 ng/ml and a non-suspicious digital rectal examination. null Methods and participants null For all enrolled patients, the Select Mdx test, the risk calculator ERSPC3 + DRE, and a prostatic magnetic resonance imaging (MRI) were carried...
#1Oleksii A. Iakymenko (UM: University of Miami)H-Index: 2
#2Isabella Lugo (UM: University of Miami)H-Index: 1
Last. Merce Jorda (UM: University of Miami)H-Index: 31
view all 0 authors...
BACKGROUND Increasing percentages of Gleason pattern 4 (GP4%) in radical prostatectomy (RP) correlate with an increased likelihood of nonorgan-confined disease and earlier biochemical recurrence (BCR). However, there are no detailed RP studies assessing the impact of GP4% and corresponding tumor volume (TV) on extraprostatic extension (EPE), seminal vesicle (SV) invasion (SV+), and positive surgical margin (SM) status (SM+). METHODS In 1301 consecutive RPs, we analyzed each tumor nodule (TN) for...
#1Hirak S. Basu (University of Texas Health Science Center at Houston)
#2Nathaniel Wilganowski (University of Texas Health Science Center at Houston)H-Index: 12
Last. George Wilding (University of Texas Health Science Center at Houston)
view all 0 authors...
BACKGROUND Most cancer cells are more glycolytic even under aerobic conditions compared with their normal counterparts. Recent evidence of tumor cell metabolism, however, shows that some tumors also increase mitochondrial oxidative phosphorylation (ox-phos) at some disease states during progression and/or development of drug resistance. Our data show that anti-androgen enzalutamide (ENZA) resistant prostate cancer (PCa) cells use more mitochondrial metabolism leading to higher ox-phos as compare...
#1Oscar Martinez (Houston Methodist Hospital)H-Index: 2
#2Christopher Murphy (Houston Methodist Hospital)H-Index: 2
Last. Ronney Abaza (Houston Methodist Hospital)H-Index: 22
view all 0 authors...
BACKGROUND Enlarged median lobes (ML) can be technically challenging, particularly during bladder-neck dissection, and may affect urinary functional outcomes of robotic radical prostatectomy (RARP). If known, the impact of potentially larger bladder necks on continence and chronic obstruction on postoperative urinary symptoms might aid patient counseling. We assessed the impact of intraoperatively identified median lobes (ML) on urinary function. METHODS We reviewed our prospective RP database f...
Top fields of study
Prostate cancer
Cancer research